Voyager Therapeutics (VYGR) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$208.9 million.
- Voyager Therapeutics' Enterprise Value rose 3950.37% to -$208.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$208.9 million, marking a year-over-year increase of 3950.37%. This contributed to the annual value of -$266.7 million for FY2024, which is 1551.01% down from last year.
- Per Voyager Therapeutics' latest filing, its Enterprise Value stood at -$208.9 million for Q3 2025, which was up 3950.37% from -$215.6 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' Enterprise Value ranged from a high of -$118.8 million in Q4 2022 and a low of -$399.6 million during Q1 2024
- In the last 5 years, Voyager Therapeutics' Enterprise Value had a median value of -$215.6 million in 2025 and averaged -$220.9 million.
- Per our database at Business Quant, Voyager Therapeutics' Enterprise Value tumbled by 9426.07% in 2023 and then soared by 4189.2% in 2025.
- Quarter analysis of 5 years shows Voyager Therapeutics' Enterprise Value stood at -$132.5 million in 2021, then rose by 10.33% to -$118.8 million in 2022, then plummeted by 94.26% to -$230.9 million in 2023, then fell by 15.51% to -$266.7 million in 2024, then rose by 21.66% to -$208.9 million in 2025.
- Its last three reported values are -$208.9 million in Q3 2025, -$215.6 million for Q2 2025, and -$236.0 million during Q1 2025.